The combination of salvianolic acid A with latamoxef completely protects mice against lethal pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i>
Dan Mu, Yongxin Luan, Lin Wang, Zeyuan Gao, Panpan Yang, Shisong Jing, Yanling Wang, Hua Xiang, Tiedong Wang, Dacheng Wang
Abstract
studies demonstrated that Sal A treatment reduced inflammation and protected mice against lethal pneumonia caused by MRSA. More significantly, full protection (a survival rate of 100%) was achieved when Sal A was administered in combination with latamoxef. Together, these results indicate that Sal A could be developed into a promising therapeutic drug to combat MRSA infections while limiting resistance development.
Topics & Concepts
Staphylococcus aureusSortase AMicrobiologyMethicillin-resistant Staphylococcus aureusPneumoniaStaphylococcal infectionsLatamoxefIn vivoMedicineVirulenceBiologyBacteriaAntibioticsBiochemistryInternal medicineGeneticsBiotechnologyCefotaximeGeneBiochemical and Structural CharacterizationToxin Mechanisms and ImmunotoxinsStreptococcal Infections and Treatments